Feel whole again
The only device able to restore sensations to limbs
Stimulation of the peripheral nervous system via our implantable neurostimulating device enables restoration of limb sensation in diabetic neuropathy, thereby lowering risks of falls, ulcers and amputations.
%20(28).png)
Sensory feedback is restored
By restoring healthy sensory feedback, SENSY brings back protective foot sensations - helping prevent ulcers, reduce falls, relieve pain, and dramatically lower the risk of amputation
Electrodes are implanted
in the nerve
Our proprietary intra-nerve electrode array interfaces directly with sensory fibers inside the peripheral nerve, reconstructing natural nerve signals and re-establishing communication with the brain.
How our closed loop system works
Sensors under the diabetic foot
Smart, wearable insoles continuously capture pressure and motion from the diabetic foot, transmitting this data wirelessly to micro-electrodes implanted within the nerve.
Cost to healthcare each
year in the US alone
$79B
$79B
Cost to healthcare each
year in the US alone
268 Million
Diabetic Neuropathy
affects millions of patients globally
Today, no existing solutions address the core cause of diabetic neuropathy complications; a disrupted sensory feedback loop.
Sensars is the only technology designed to completely restore sensory feedback to the extremities with high specificity and coverage.
How diabetic neuropathy works
How we reduce risks of complications
268 Million
People worldwide with diabetic neuropathy risk losing sensations in feet
Our Partners
We have established deep partnerships with the world's most prestigious institutions, clinics and accelerators.
We have also been granted numerous global awards for our breakthrough technology.
Clinical Partnerships
.png){kind=logo}
Academic & Industrial Partners
Grants & Awards
Latest Awards & Features
Masschallenge Silver Award Winner '22
MIT Under 35
News
SENSY: Groundbreaking Technology for Diabetic Neuropathy
Neurotech Reports highlights Sensars as an emerging company with groundbreaking technology for the treatment of painful diabetic neuropathy. Read More >
.png)
Sensars gets funding of €1.1M to advance its SENSY product
Lausanne, Munich, May 2024 – Sensars, a pioneering leader in neuromodulation technology, is proud to announce significant advancements in its mission to revolutionize the treatment of chronic pain and sensory loss. Read More >
Sensars coordinates a €3 million grant to test its bionic prosthetics
Sensars has received a 3 million EUR grant as part of the European Union’s Horizon Research and Innovation program. The startup will coordinate and use the funds to further develop and test its product - the neuroprosthetic system. Read More >
Top '20 Most Innovative Companies to Watch, 2022
Sensars Named In Business Worldwide Magazines' Top '20 Most Innovative Companies to Watch, 2022. Read More >
Sensars receives FDA Breakthrough Device Designation
Two Swiss start-ups have been granted FDA Breakthrough Device Designation recently: AMF for its Sigi Insulin Management system and Sensars for its system providing sensory feedback for those with limb loss to improve prosthesis function. Read More >
Looking Ahead
Neurotech of the future
Our neurotechnology creates countless new possibilities in the future, from prosthetic control to obesity & depression treatment & beyond.